The future of medical cannabis development in Europe
European Pharmaceutical Review
JULY 13, 2023
3 With established drug development pathways, we are accustomed to a rigid structure of translation from bench to bedside. It is estimated that only one in 10 drugs that enter Phase I trials are subsequently licensed by the US Food and Drug Administration (FDA). This could lead to significant research waste.
Let's personalize your content